Skip to main content

01.12.2014 | Research | Ausgabe 1/2014 Open Access

Italian Journal of Pediatrics 1/2014

Efficacy of Grintuss® pediatric syrup in treating cough in children: a randomized, multicenter, double blind, placebo-controlled clinical trial

Italian Journal of Pediatrics > Ausgabe 1/2014
Mario Canciani, Vitalia Murgia, Davide Caimmi, Sreedhar Anapurapu, Amelia Licari, Gian Luigi Marseglia
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1824-7288-40-56) contains supplementary material, which is available to authorized users.

Competing interests

VM has been a scientific advisor and/or a speaker on educational meetings on Phytotherapy for several companies: Aboca, Dicofarm, Cristalfarma, Labomar, Lemuria, Milte. The other authors declare that they have no competing interests.

Authors’ contributions

MC and GLM designed the study; MC, VM and GLM drafted the manuscript; DC and AL were responsible for data acquisition; SA was responsible for data management and statistical analysis. All authors read and approved the final manuscript.



Cough is an extremely common problem in pediatrics, mostly triggered and perpetuated by inflammatory processes or mechanical irritation leading to viscous mucous production and increased sensitivity of the cough receptors. Protecting the mucosa might be very useful in limiting the contact with micro-organisms and irritants thus decreasing the inflammation and mucus production. Natural molecular complexes can act as a mechanical barrier limiting cough stimuli with a non pharmacological approach but with an indirect anti-inflammatory action.


Aim of the study was to assess the efficacy of a medical device containing natural functional components in the treatment of cough persisting more than 7 days.


In this randomized, parallel groups, double-blind vs. placebo study, children with cough persisting more than 7 days were enrolled. The clinical efficacy of the study product was assessed evaluating changes in day- and night-time cough scores after 4 and 8 days (t4 and t8) of product administration.


In the inter-group analysis, in the study product group compared with the placebo group, a significant difference (t4 study treatment vs. t4 placebo, p = 0.03) was observed at t4 in night-time cough score.
Considering the intra-group analysis, only the study product group registered a significant improvement from t0 to t4 in both day-time (t0 vs. t4, p = 0.04) and night-time (t0 vs. t4, p = 0.003) cough scores.
A significant difference, considering the study product, was also found in the following intra-group analyses: day-time scores at t4 vs. t8 (p =0.01) and at t0 vs. t8 (p = 0.001); night-time scores at t4 vs. t8 (p = 0.05), and at t0 vs. t8 (p = 0.005). Considering a subgroup of patients with higher cough (≥3) scores, 92.9% of them in the study product group improved at t0 vs. t4 day-time.


Grintuss® pediatric syrup showed to possess an interesting profile of efficacy and safety in the treatment of cough persisting more than 7 days.
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2014

Italian Journal of Pediatrics 1/2014 Zur Ausgabe

Neu im Fachgebiet Pädiatrie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Pädiatrie und bleiben Sie gut informiert – ganz bequem per eMail.